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Abstract
Background: Schistosome parasites cause schistosomiasis, one of the most important infectious diseases worldwide. For
decades Praziquantel (PZQ) is the only drug widely used for controlling schistosomiasis. The absence of a vaccine and fear of
PZQ resistance have motivated the search for alternatives. Studies on protein kinases (PKs) demonstrated their importance
for diverse physiological processes in schistosomes. Among others two Abl tyrosine kinases, SmAbl1 and SmAbl2, were
identified in Schistosoma mansoni and shown to be transcribed in the gonads and the gastrodermis. SmAbl1 activity was
blocked by Imatinib, a known Abl-TK inhibitor used in human cancer therapy (Gleevec/Glivec). Imatinib exhibited dramatic
effects on the morphology and physiology of adult schistosomes in vitro causing the death of the parasites.
Methodology/Principal Findings: Here we show modeling data supporting the targeting of SmAbl1/2 by Imatinib. A
biochemical assay confirmed that SmAbl2 activity is also inhibited by Imatinib. Microarray analyses and qRT-PCR
experiments were done to unravel transcriptional processes influenced by Imatinib in adult schistosomes in vitro
demonstrating a wide influence on worm physiology. Surface-, muscle-, gut and gonad-associated processes were affected
as evidenced by the differential transcription of e.g. the gynecophoral canal protein gene GCP, paramyosin, titin,
hemoglobinase, and cathepsins. Furthermore, transcript levels of VAL-7 and egg formation-associated genes such as
tyrosinase 1, p14, and fs800-like were affected as well as those of signaling genes including a ribosomal protein S6 kinase
and a glutamate receptor. Finally, a comparative in silico analysis of the obtained microarray data sets and previous data
analyzing the effect of a TGFbR1 inhibitor on transcription provided first evidence for an association of TGFb and Abl kinase
signaling. Among others GCP and egg formation-associated genes were identified as common targets.
Conclusions/Significance: The data affirm broad negative effects of Imatinib on worm physiology substantiating the role of
PKs as interesting targets.
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Introduction
Schistosomiasis is an infectious disease of worldwide importance
caused by parasitic platyhelminthes of the class trematoda such as
Schistosoma haematobium, S. intercalatum, S. japonicum, S. mansoni, or S.
mekongi. About 780 million people are at risk of schistosomiasis,
and more than 240 million infections emerge annually requiring
treatment [1,2]. Adult schistosomes live in the abdominal veins of
their vertebrate hosts. Only if paired, females produce eggs, half of
which reach the gut lumen (e.g. S. mansoni) or the bladder (S.
haematobium), to be transported to the environment for continuing
the life-cycle. Gut invasion is accompanied by inflammatory
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processes. The remaining eggs migrate through the blood stream
and become trapped in spleen and liver tissue, where granulomas
are formed and fibrosis occurs, leading to hepatosplenomegaly and
liver cirrhosis [3,4]. The disease has a high socioeconomic impact
causing annual losses of 1.7 to 4.5 million disability adjusted life
years (DALYs) of humans living in endemic areas [5,6], but
tourists and travelers can also be affected [7]. Besides humans,
animals including cattle can get infected, too, which causes
economic losses [8–11].
Since there is no vaccine available yet, the main strategy to
control schistosomiasis is the regular use of drugs, of which three
have the potency to kill schistosomes. Of the drugs available today
Metrifonate is active against S. haematobium only and Oxamniquine
is active against S. mansoni only. In contrast to these limitations,
although its effectiveness against immature stages is limited
Praziquantel (PZQ) is effective against all important schistosome
species mainly affecting adults [12]. This and its low price have
promoted PZQ as the drug of choice, which is also used in large-
scale treatment programs today [13,14]. However, drug resistance
has been recognized as a potential problem since several studies
demonstrated PZQ resistance to be inducible in laboratory
settings, and field studies provided first indications for the
possibility of reduced PZQ efficacy [15–18]. Furthermore,
multidrug transporters were discovered in schistosomes, of which
one was shown to respond to a PZQ challenge [19]. With respect
to these facts it is commonly accepted that new drugs are required
urgently. To this end research on signal transduction processes in
S. mansoni has opened new perspectives.
Protein kinases (PKs) are highly conserved signal transduction
molecules in the animal kingdom and known to be involved in
diverse biological processes such as cell growth and differentiation
[20]. Thus PK deregulation can lead to cancer development [21–
22]. This prompted the search for inhibitors, and meanwhile a
number of anticancer drugs targeting PKs are approved for use in
humans [21–24]. Different studies elucidating principles of
schistosome development have shown that PKs play important
roles during parasite development [25–30]. Due to this, and to the
fact that schistosomes can be kept in culture, providing access to
adults ex vivo, several studies were conducted to investigate whether
anticancer drugs would negatively affect PK-controlled processes
in schistosomes and cause phenotypic consequences in adults.
Indeed, targeting a variety of different kinases using different drugs
with PK-inhibiting activities not only showed a negative influence
on the reproductive biology of parasites but also remarkable effects
on other physiological processes and/or survival in vitro [29–37].
Among the PKs studied in more detail were protein tyrosine
kinases (PTKs) such as Abl kinases, three of which exist in S.
mansoni. SmAbl1 and SmAbl2 exhibit high sequence similarities to
conserved Abl-kinases [38], whereas SmTK6 revealed a Src/Abl
hybrid character that was confirmed by structural and biochemical
studies [39]. Imatinib was used as an inhibitor to analyze Abl-PK
activities in adult S. mansoni [38,39]. Also known as Glivec
(Gleevec; Novartis) Imatinib is a small-molecule inhibitor acting as
a competitive antagonist of adenosine triphosphate (ATP) binding
to Abl-PK, which is applied successfully in human cancer therapy
[40]. Structural analyses revealed that the S. mansoni Abl-PKs
possess the majority of amino acid residues known from studies
with the human Abl-kinase to interact with Imatinib [38,41].
Furthermore, the Xenopus oocyte system was shown to be suitable
to test the catalytic activity of schistosome tyrosine kinases (TKs)
[31,39]. Thus it was demonstrated that SmAbl1-TK, SmTK6-
TK, and SmTK3-TK were able to induce 100% germinal vesicle
breakdown (GVBD) [39]. Using competitive GVBD assays it was
further demonstrated that Imatinib negatively influenced the
kinase activities of SmAbl1-TK (0% GVBD at 1 mM) and
SmTK6-TK (0% GVBD at 100 mM). Although the latter required
a 100-fold higher concentration compared to SmAbl1-TK, this
was explained by the unusual Src/Abl hybrid character of
SmTK6. Herbimycin A (Herb A), a Src-TK inhibitor, was not
able to fully reduce the GVBD-inducing activity of SmAbl1 (60%
GVDB at 10 mM) in contrast to SmTK6, whose activity was fully
suppressed at this concentration. The enzymatic activity of
SmTK3, a Src kinase used as control, was fully suppressed by
Herb A (0% GVBD at 0.01 mM) but revealed nearly no decrease
under the influence of Imatinib (still 90% GVBD at 100 mM),
confirming the specificity of these inhibitors [39].
Treating adult schistosomes with Imatinib in vitro led to dose-
and time-dependent effects such as reduced pairing stability, the
occurrence of bulges and swellings along the body and, finally, the
death of the worms. Microscopic analyses showed not only
morphological changes within the gonads of both genders, which
appeared disordered, defective in differentiation, and in part
apoptotic, but also a detachment and degradation of the
gastrodermis. Its complete collapse explained the observed death
of the parasites [38]. In a follow-up study it was shown that
Dasatinib and Nilotinib, second generation Abl-PK inhibitors of
high selectivity, were less effective compared to Imatinib in causing
severe or even lethal effects on adult schistosomes in vitro. Since
Dasatinib and Nilotinib were designed to be even more specific for
mutated forms of the human Abl-PK, it was concluded that the
more specialized the inhibitor for the human kinase is, the more
efficacy for the schistosome kinase gets lost [42].
Because in situ hybridizations detected various regions within
adult S. mansoni where these Abl- and Abl-like PKs of S. mansoni
were transcribed [36,38], pointing to different physiological
functions these kinases may be involved in, we were interested in
investigating the effects of Imatinib at the gene transcription level
in treated schistosomes. Besides confirming that Imatinib also
affected SmAbl2 kinase activity in a heterologous test system, a
transcriptome study was performed by microarray analyses and
Author Summary
Schistosomiasis is an infectious disease caused by schisto-
some parasites, affecting millions of people worldwide.
The pathogenic consequences of schistosomiasis are
caused by the eggs inducing severe organ inflammations.
Praziquantel is widely used to treat schistosomiasis;
however, there is fear of resistance developing. Research
in the last decades has provided strong evidence for the
importance of protein kinases controlling physiological
processes in schistosomes. Two Abl-kinases were discov-
ered, whose activities are blocked by Imatinib, an inhibitor
known as Gleevec/Glivec from human cancer therapy. In
vitro, Imatinib treatment led to dramatic effects on
morphology and physiology and to the death of adult
schistosomes. Besides modeling of the schistosome Abl-
kinases we investigated the effect of Imatinib on gene
expression in adult S. mansoni by performing transcrip-
tomics and discovered a wide influence on the transcrip-
tion of genes involved in surface-, muscle-, gut- and
gonad-associated processes. Comparative in silico analyses
with data from a previous study indicated a yet unknown
association of TGFb and Abl-kinase signaling in schisto-
somes. Among others the gynecophoral canal protein
gene GCP was identified as a common target. The data
obtained demonstrate a substantial influence of Imatinib
on physiological processes in adult schistosomes support-
ing the role of protein kinases as interesting targets.
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qRT-PCR verification experiments. Strong evidence was obtained
that gene transcription is widely influenced supporting the view
that a variety of physiological processes have been affected by this
Abl-PK inhibitor. This is in line with previous hypotheses
suggesting that PKs, due to their pleiotropic and fundamental
roles for schistosome biology, are substantiated targets for novel
strategies to treat schistosomiasis [42,43]. Furthermore, first
evidence was obtained that Abl-kinase activities could be part
of/or associated with transforming growth factor b (TGFb)
signaling in schistosomes.
Materials and Methods
Ethics statement
Experiments with hamsters were performed in accordance with
the European Convention for the Protection of Vertebrate
Animals used for Experimental and other Scientific Purposes
(ETS No 123; revised Appendix A) and were approved by the
Regional Council (Regierungspraesidium) Giessen (V54-19 c 20/
15 c GI 18/10).
Parasite stock
Biomphalaria glabrata as intermediate snail-host, and hamsters
(Mesocricetus auratus) as final host were used to maintain the parasite
cycle of S. mansoni [44]. Adult worms were isolated from hamsters
by hepatoportal perfusion 42 days post infection.
Homology modeling
Chemical Computing Group’s MOE 2011 (http://www.
chemcomp.com/) molecular modeling suite was used for the
homology modeling. The highly conserved catalytic tyrosine
domains [38] of human Abl1 (2HYY) and Abl2 (3GVU) were
used as templates for the model building of SmAbl1 and SmAbl2,
respectively. The two homologous sequences were aligned using
MOE’s kinase constraints, and the models were built using the
Amber99 force field with R-Field solvation. Crystallographic water
molecules in an H-bond network with the ligand Imatinib and the
ligand itself were used as ‘‘Environment for Induced Fit’’ during
model building. Intermediates were refined to medium using the
GB/VI scoring, while the final model was refined to Fine with an
RMS Gradient of 0.5.
Molecular Docking
Molecular Docking was carried out using Cambridge Crystal-
lographic Data Centre’s GOLD suite 2.5 (http://www.ccdc.cam.
ac.uk/). Imatinib was sketched in 2D and converted to 3D using
Molecular Networks’ CORINA (http://www.molecular-networks.
com/). Docking was performed using the Chemscore scoring
function with kinase parameters, and the binding site was defined
using the position of the Imatinib ligand as modeled in the SmAbl1
and SmAbl2 homology models. Parameters for the genetic
algorithm were set to auto. Water molecules used for the model
building were allowed to participate in the docking.
GVBD assays in Xenopus oocytes
Sequences of the tyrosine kinase (TK) domains of SmAbl1,
SmAbl2, SmTK6, and SmTK3 were obtained by PCR amplifi-
cation (primers used are given in Supplementary data S1) and
cloned into the plasmid pcDNA3.1B (Invitrogen), which contained
a T7 promoter for in vitro transcription. The resulting constructs
SmAbl1-TK, SmAbl2-TK, SmTK6-TK, and SmTK3-TK were
sequenced confirming intact open reading frames (ORFs). The
plasmid constructs were linearized by PmeI and cRNAs were
generated using the T7 mMessage mMachine Kit (Ambion, USA).
This way capped messenger RNAs (cRNAs) were synthesized in
vitro and analyzed as previously described [31,38], before they
were injected into stage VI oocytes of Xenopus laevis. To this end
each oocyte was injected with 60 ng cRNA in the equatorial plane,
followed by incubation in ND96 medium at 19uC. GVBD
(germinal vesicle breakdown) activity was determined according
to the appearance of a white spot at the animal pole 18 h following
injections. As shown before, this system was used successfully to
monitor schistosome kinase activities [31,38,39]. Here it was used
to investigate kinase activities under the influence of Imatinib
(Enzo Life Sciences; 170 mM stock solution in water), an Abl-
kinase inhibitor, or the Src kinase inhibitor Herbimycin A (Herb
A) as control (Tocris Bioscience; 10 mM stock solution in DMSO).
Pools of 10 oocytes each were injected with SmAbl1-TK, SmAbl2-
TK, SmTK3-TK, or SmTK6-TK cRNA and placed in ND96
containing different concentrations of Imatinib (0.01 mM to
100 mM final) or Herb A (0.0001 mM to 10 mM final). As negative
control, non-injected oocytes were used. As positive controls,
oocytes were incubated with the natural hormonal stimulus
progesterone leading to 100% GVBD without further manipula-
tion [45].
Schistosome in vitro-culture and inhibitor treatments
Perfusion was done with M199 medium (Gibco). Paired adult
worms were collected using fine tweezers and washed with M199
medium (2x). Subsequently, they were maintained in culture in
M199 supplemented with FCS (Gibco; 10%), HEPES (Sigma;
1 M, 1%), and antibiotic/antimycotic mixture (Sigma; 1%) at
37uC and 5% CO2 [36,38]. Inhibitor treatment was performed for
24 h or 48 h with 50 mM Imatinib (Imatinib mesylate,
C29H31N7O?CH3SO3H, dissolved in water; Enzo Life Sciences)
as previously described [38]. Control couples were kept in culture
for 24 h or 48 h without inhibitor addition but otherwise treated
using the same conditions. During the treatment periods, pairing
stability and vitality were checked regularly. We defined pairing
stability of couples when males kept their female partners within
the gynecophoral canal while being sucked with their ventral
suckers to the Petri dish. When couples separated, or when males
stopped sucking to the Petri dish and/or lay on the side (a sign of
decreasing vitality), the appropriate worms were not used for
experiments and removed. After completion of treatment, the
couples (inhibitor-treated and control) were carefully separated
using featherweight tweezers, immediately shock-frozen in liquid
nitrogen, and stored at 280uC.
RNA isolation and microarray experiments
Trizol (Invitrogen) was used to extract RNA from treated or
control worms (combined sexes in both cases) followed by a
DNAse digestion (RNAeasy kit; Qiagen). The quality of RNA was
checked by microfluidic electrophoresis (Bioanalyzer; Agilent
Technologies). For microarray experiments a S. mansoni custom-
designed oligonucleotide platform (60-mers) was used containing
44,000 probes representing nearly the complete S. mansoni and S.
japonicum transcriptome (Agilent Technologies; [46,47]). All
associated information (probes, annotation) is available at Gene
Expression Omnibus (GEO) under the accession number
GPL8606.
For the microarray experiments RNA from treated and control
males and females (300 ng each for biological replicates) was used
for cDNA amplification followed by Cy3 and Cy5 labelling during
in vitro transcription (Quick Amp Labelling Kit, two colors; Agilent
Technologies). Dye-swap approaches were done as internal
technical replications for each sample. Three microarray hybrid-
izations were performed for each sample (inhibitor treatment for
Imatinib-Influenced Transcription in Schistosomes
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24 and 48 h as well as control), which included two technical
replicates for each of the three biological replicates. As probe for
hybridization, 825 ng cRNA of each labelled inhibitor sample was
used and combined with a control sample labelled with the
opposite dye. Hybridization was done at 65uC for 17 h with
rotation followed by slide washing (according to the Agilent
manual) and scanning (Gene Pix 4000B Scanner; Molecular
Devices). Raw data were acquired using the Feature Extraction
software (Agilent Technologies). They are available under GEO
study number GSE53154. For subsequent data analyses, genes
were considered as transcribed only if the corresponding probe
had a signal significantly higher than background (using default
parameters from the Feature Extraction software and considering
the ‘‘IsPosAndSig’’ result from the output). In addition, signals of a
probe had to occur in at least 75% of all replicates and in at least
one of the two conditions (inhibitor-treated or control) indepen-
dent of the length of cultivation (24/48 h treatment versus 24/
48 h untreated control). The quality of the microarray expression
data was assessed by the overall Pearson correlation among
technical replicates, which was found to be in the range of 0.93 to
0.99 (average 0.98). LOWESS algorithm was used for normalisa-
tion of intensities [48], and the log2ratios were calculated between
inhibitor-treated and control groups. Finally, the filtered data were
analysed on the basis of the updated genome annotation to
eliminate redundancy of the probes per gene [49,50]. Inspection of
box plots revealed that intensities from both dye channels of all
technical and biological replicates were in a similar range, showing
that no additional normalization steps were necessary.
SAM (Significance Analysis of Microarrays) was used [51] to
detect genes with a significant change in transcript level. Data sets
for the two treatment periods (24 h and 48 h) were analysed by
one-class analysis, in which transcripts were evaluated that showed
the same direction of regulation for both time points (sustained
regulation direction). Here, genes with a q-value #0.01 were
considered as significantly differentially transcribed between the
inhibitor-treated and the control worm populations comprising
protein-coding genes and putative antisense-oriented oligonucle-
otide probes (labelled as ‘‘to be used in analysis = YES’’ in the
updated annotation of the array [49,50]). Spotfire was used for
hierarchical clustering [52]. For first functional analyses of
differentially transcribed protein-coding genes, Gene Ontology
(GO) enrichment analysis was performed [53] using the software
tool Ontologizer [54]. Parent-child union [55] was used to detect
categories containing enriched genes, and the p-value was adjusted
according to Benjamini-Hochberg (BH) correction [56]. For
identifying potential candidates for further analyses and their
putative involvement in hypothesized pathways, Ingenuity Path-
way Analyses (IPA; http://www.ingenuity.com; [57]) were
performed in addition, as described before [47]. IPA provides
curated information from the literature for human, mouse and rat
models about canonical pathways, regulated molecular networks,
including signal transduction cascades (of which some are involved
in human cancer or other diseases), and regulated transcription
factors and their putative targets. To use this tool all S. mansoni
genes were annotated with the corresponding human homolog
and uploaded to IPA along with their corresponding microarray
transcription measurements.
The validity of the obtained results of qRT-PCRs (see below)
and microarrays was determined by Spearman’s rank correlation
coefficient (rs) [58].
Quantitative RT-PCR experiments
The reliability of the transcriptional changes detected by
microarray analyses was tested by quantitative RT-PCR
(qRT-PCR) analyses of a number of genes. RNAs of inhibitor-
treated or control couples were isolated by TriFast (PeqLab), and
1 mg each was reverse transcribed (QuantiTect Reverse Tran-
scription kit; Qiagen). Following cDNA dilution 1:20, qRT-PCRs
were done using Rotor Gene Q (Qiagen). Amplification rates were
determined by SYBRGreen incorporation (PerfeCTa SYBR
Green Super Mix; Quanta). Melting point analyses were done to
distinguish between the specific amplification product and
unspecific primer-dimer formation following each qRT-PCR
analysis. For primer design, the software Primer 3 Plus was used
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.
cgi). The expected amplification products were between 140–
160 bp in size. Primers were designed flanking predicted introns to
be able to differentiate between cDNA and genomic DNA, and
melting points were between 59uC–62uC depending on sequence
composition. A list of all primers used, which were commercially
synthesised by Biolegio (Netherlands), is shown in Supplementary
data S1.
Standard reference genes normally used for relative quantifica-
tion analyses such as a-tubulin, actin, Cu/Zn SOD (superoxide
dismutase), or histone showed regulation following inhibitor
treatment. Therefore, absolute quantification was performed on
the basis of standard curves generated by purified PCR products
(used in dilution series) [59]. Fold changes are given where
appropriate. As a basis for comparing microarray and qRT-PCR
results, log2ratios (treated/control) were calculated as described
before [47,60]. The efficiency of each qRT-PCR was evaluated to
be between 90–100%. Spearman’s rank correlation coefficient (rs)
was assessed to validate the ratios obtained from qRT-PCRs and
microarrays [58,61,62].
In silico analyses
In addition to those already mentioned, the following public
domain tools were used: SchistoDB (http://www.schistodb.net; [63]),
BLASTx (http://www.ncbi.nlm.nih.gov/BLAST), the Welcome
Trust Sanger Institute S. mansoni OmniBlast (http://www.sanger.ac.
uk/cgi-bin/blast/submitblast/s_mansoni/omni), BLAST (http://
blast.ncbi.nlm.nih.gov/), and Gene Cards, which is a database of
human genes providing concise genome-related information on all
known and predicted human genes, to authenticate IPA-identified
gene acronyms (http://www.genecards.org).
Results
Homology modeling revealed structural conformity
between human and schistosome Abl-kinases
On the basis of their human counterparts, homology models of
the S. mansoni Abl kinase 1 and 2 were created which corresponded
well with the protein template structures 2HYY (human Abl 1) and
3GVU (human Abl 2). The ten highest scoring docking poses of
Imatinib in the homology model of SmAbl2 were found in good
structural agreement with the crystal structure pose of Imatinib in
the human Abl2 crystal structure (Figure 1 A; SmAbl1 data not
shown). The highest scoring docking pose is virtually identical to
the crystal structure pose (Figure 1 B). While human Abl2 forms
seven directed interactions with Imatinib (Figure 2), for the
SmAbl2 homology model four directed interactions were detected
(Figure 1 C, Figure 2). Two out of the four SmAbl2 interactions
are shared with the human Abl2 interactions (Figure 2). For
SmAbl1 the situation was similar. Key residues involved in direct
interactions with Imatinib in the human Abl proteins were found
to be conserved for all four protein sequences. Four out of the six
directed interactions were also detected for the SmAbl1 homology
model. In contrast to human Abl 1, one of these residues (D568)
Imatinib-Influenced Transcription in Schistosomes
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did not interact directly with Imatinib; however, it did via an H-
bond network involving a water molecule. Since we docked
Imatinib to homology models, the recovery of individual directed
interactions should not be overstated. Although we docked
Imatinib to homology models, the data clearly indicated that
Imatinib is able to bind both SmAbl1 and SmAbl2.
S. mansoni Abl-TK activities are inhibited by Imatinib
An inhibitor swap-like approach [38] was used to test the
enzymatic activity of SmAbl2, for its susceptibility towards
Imatinib and Herb A. To this end, cRNA encoding the TK
domain of SmAbl2 (SmAbl2-TK) was injected into Xenopus oocytes
under selection conditions using different inhibitor concentrations.
GVDB was monitored as read out, and the results compared to
SmAbl1, SmTK6 and SmTK3 [38]. Under Herb A selection,
SmAbl2-TK induced 100% GVBD at 1 mM and still 90% GVBD
at 10 mM (Figure 3). The Src-TK SmTK3 and the Src/Abl-hybrid
TK SmTK6 were completely inhibited by Herb A inducing
GVBD at concentrations of 0.01 mM (SmTK3), or 10 mM
(SmTK6) [39]. Using Imatinib, however, SmAbl2-TK enzymatic
activity was reduced to 70% GVBD-inducing capacity at 0.01 mM
and completely suppressed GVBD at 0.1 mM. At the latter
concentration still 90% GVBD was observed for SmAbl1-TK,
whose activity was completely suppressed using 1 mM Imatinib
(Figure 3). These results showed that Imatinib effectively inhibits
both Abl kinases of S. mansoni, which is supported by the modeling
data presented above.
Transcriptome analyses of inhibitor-treated adults
exhibited wide-ranging transcriptional changes
Based on our previous findings of remarkable effects of Imatinib
on morphology, physiology, and survival of adult S. mansoni in vitro
[38,42], we focused on the elucidation of molecular effects induced
by this inhibitor. To this end, a large-scale transcriptional analysis
was performed using a microarray platform representing nearly
the complete S. mansoni and S. japonicum transcriptomes [46,47].
Since in previous experiments treatment with 50 mM Imatinib
showed slight effects after 24 h and strong effects after 48 h
treatment [38], we anticipated that these treatment profiles
represented starting (24 h) and peak points (48 h) of the effects
induced, thus being interesting for analysis. Therefore, the 50 mM
concentration and both time points were chosen for comparative
Figure 1. Homology models of human and schistosome Abl kinases. Panels A to C: Structural comparisons of the molecular docking
solutions of the SmAbl2 homology model versus the human Abl2 crystal structure (3GVU). Both protein structures are shown in ribbon
representation, the SmAbl2 homology model is colored yellow, while the human Abl2 crystal structure is colored red. A: Structural superposition of
the two protein structures. The ten highest scoring docking solutions for Imatinib in the SmAbl2 homology model were depicted in stick
representation in atom color, the crystal structure pose of Imatinib in the human Abl2 crystal structure is depicted in ball-and-stick representation
colored red. Hydrogen atoms were omitted for visibility reasons in the depiction. The RMSD value of the template and the model structure resulted in
a Ca RMSD (root-mean-square deviation) value of 0.765 A˚ of the corresponding 245 amino acid residues. B: Close-up view of the binding sites of the
two protein structures. The top-scored pose of Imatinib in the SmAbl2 homology model was depicted in stick representation with light-grey carbon
atoms, the crystal structure pose of Imatinib in human Abl2 was depicted in stick representation with dark grey carbon atoms. C: Close-up view of the
binding site of SmAbl2 homology model. Imatinib engages in four directed interactions to surrounding amino acid residues, depicted by light blue
dashed lines.
doi:10.1371/journal.pntd.0002923.g001
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transcriptomics. Based on the results of the GVBD assays it was
anticipated that 50 mM Imatinib would not induce potential off-
target effects through co-influencing Src kinases such as SmTK3
since its inhibition will not occur using this inhibitor concentration
[39; this study]. With this set-up, the expectation was to find genes
differing in their transcript levels under inhibitor influence. It was
hypothesized that transcript levels of genes strongly regulated by
signaling pathways including SmAbl1/2-kinases would show a
continuous tendency of regulation during the treatment period of
48 h representing sustained transcriptional changes.
Following microarray hybridization and data evaluation a one-
class statistical analysis was performed that revealed sustained
transcriptional changes of 1429 significantly differentially transcribed
genes which were up-regulated following Imatinib-treatment. Of
these, 1094 were protein-coding genes (Supplementary data S2, S3).
The remaining transcripts represented antisense RNAs, intronic and
UTR sequences. Among the protein-coding genes were candidates
coding for serine/threonine PKs, PTKs, proteins with female-
preferential or -specific functions such as egg synthesis, transcription
factors, muscle-associated proteins, small GTPases, heat-shock
proteins, and signal transduction/associated proteins (Supplemen-
tary data S4). Furthermore, 939 protein-coding genes were found to
be significantly down-regulated. These genes potentially code for
cathepsins, lipoproteins, VAL(venome allergen-like) proteins, gluta-
mate receptors and further transporters, the gynecophoral canal
protein (GCP), motor and/or muscle proteins, drug efflux proteins,
transmembrane receptors, calmodulin and other calcium binding
proteins, histones, spermatogenesis-/testis-associated proteins, a
morphogen-binding protein, signal transduction (-associated) pro-
teins, and a cell adhesion protein (Supplementary data S5).
GO analyses of differentially transcribed genes revealed
ontology categories enriched with genes being up- or down-
regulated (BH adjusted p-value #0.05; threshold = 0.1). Examples
of GO categories represented in the up-regulated genes were: gene
expression and transcription (Biological process), myosin complex
(Cellular compenent), kinase activity and transcription factor
activity (Molecular Function) (Supplementary data S4, S6). Within
the data set of down-regulated genes, GO categories were found
for enriched genes coding for functions such as e.g. transmem-
brane transport or cell surface receptor-linked signalling pathways
(Biological process), membrane and microtubule-cytoskeleton/
associated complex (Cellular component), and signal transducer
activity, transporter activity or cysteine-type endopeptidase activity
(Molecular function) (Supplementary data S5, S7).
Using IPA, the following five networks were identified, which
were enriched with proteins coded by differentially transcribed
genes involved in the following functions: (1) Protein Degrada-
tion, Protein Synthesis, Tumor Morphology (adjusted p-value
10280), (2) RNA Post-Transcriptional Modification, DNA Rep-
lication, Recombination, and Repair, Cellular Assembly and
Organization (adjusted p-value 10269), (3) Post-Translational
Modification, Protein Folding, Carbohydrate Metabolism (adjusted
p-value 10260), (4) Developmental Disorder, Gene Expression,
Genetic Disorder (adjusted p-value 10240), and (5) Carbohydrate
Metabolism, Drug Metabolism, Lipid Metabolism (adjusted p-value
10239) (Supplementary data S8). Among the molecules with the
largest fold-changes of transcription was a potential pseudo-
glutamine synthetase (LGSN) strongly (about 9-fold) up-regulat-
ed, which in the human system is reported to have a chaperone
function for the reorganization of intermediate filaments acting as
a component of the cytoskeleton [64]. Amongst the strongly
down-regulated (about 8 to 11-fold) transcripts were those
encoding peptidases such as cathepsins (CatK, CatS, CatL),
which are members of the peptidase C1 protein family and
known in humans to participate in protein processing during
immunological processes and several disease-associated patholo-
gies [65,66]. In summary, a number of processes were highlighted
by both GO analyses and IPA that were influenced by inhibitor
treatment pointing to candidate genes such as cathepsins for
further analyses.
Figure 2. Alignment of the TK domains of human and schistosome Abl kinases. Alignment: Structural alignment of the binding sites of
human (HsAbl1, HsAbl2) and S. mansoni (SmAbl1, SmAbl2) Abl kinases focused on the highly conserved catalytic tyrosine domain [37]. Amino acid
residues partnering in directional interactions with Imatinib are highlighted ocher and red for SmAbl1/2 and HsAbl1/2, respectively. Amino acids
D568 and K457 of SmAbl1 are colored light teal, because they are not direct interaction partners to Imatinib but utilize a water molecule.
doi:10.1371/journal.pntd.0002923.g002
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Confirmation of selected differentially transcribed genes
by quantitative RT-PCR
The selection of candidates for qRT-PCR experiments to verify
differential transcription was based on GO and IPA results, but
also on literature studies including the Imatinib-induced pheno-
types in adults obtained previously (negative effects on pairing-
stability, oogenesis and spermatogenesis, integrity of the gastro-
dermis, and locomotion [38,42]). Since GO and IPA analyses
indicated influences of Imatinib treatment on endopeptidase
activity and cathepsins, respectively, we chose cathepsin K
(Smp_139240) and cathepsin B (Smp_085180). The latter was
already shown to be active in the gut [67]. This applies also to the
selected hemoglobinase (Smp_075800), which was localized to the
gut [68]. Venom allergen-like proteins (VALs) of platyhelminths
are members of the SCP/TAPS (Sperm-Coating Protein/Tpx-1/
Ag5/PR-1/Sc7) protein superfamily and hypothesized to play not
only roles in spermatogenesis but also beyond [69], which led to
the choice of VAL7 (Smp_070240). The metabotropic glutamate
receptor (Smp_128940; [70]) was selected as a representative for
cell surface receptors and its potential role in the nervous system of
adult male and female schistosomes [71]. Finally, GCP was
included due to its hypothesized role in male-female interaction
[72]. The results of the qRT-PCR experiments, which were
performed with the RNA of schistosome couples following 48 h
Imatinib treatment, confirmed in each case the down-regulation of
these transcripts (Figure 4).
Since the GO analysis of up-regulated genes pointed to
muscular activities (myosin complex within the ontology cellular
component) but also to signal transduction (kinase activity within
the ontology molecular function), further candidates were selected
for qRT-PCR. Among these were paramyosin (Smp_129550) and
titin (Smp_105020), both proteins involved in muscle activity
[73,74], and a ribosomal protein S6 kinase (Smp_017900) due to
its potential role as a MAPK-activated PK in signalling processes
controlling diverse processes including survival [75,76]. Further-
more, HSP70 (Smp_106930) was chosen due to its known roles in
stress response and signal transduction processes, but also as egg-
shell component in schistosomes [77–79]. The results of the qRT-
PCR analyses confirmed up-regulation in each case (Figure 5).
Unexpectedly, a manual data screen indicated that a number of
egg production-related genes were significantly up-regulated
following Imatinib treatment such as the egg-shell precursor
proteins p14 (Smp_131110; [80]), fs800-like (Smp_000270; [79]),
a predicted egg-shell precursor protein (Smp-000430; [47]), and
the eggshell protein cross-linking tyrosinase SmTYR1 (Smp_
050270; [81]). Also for these genes, qRT-PCR confirmed up-
regulation following Imatinib treatment (Figure 5).
The results obtained for the qRT-PCR analyses of all studied
genes significantly correlated to the microarray data according to
Spearman’s Correlation Coefficient (rs = 0.784, p,0.001; [58]).
Extended analyses indicated that Imatinib treatment can lead to
a sustained effect on specific genes. By qRT-PCR analyses of RNA
of couples treated with Imatinib for 24 h or 48 h, the amounts of
gene transcripts increased or decreased over time as demonstrated
exemplary by the analyses of three genes. Compared to 24 h
treatment higher transcript levels were determined for the
ribosomal S6 kinase after 48 h (Supplementary data S9), whereas
transcript levels declined for hemoglobinase and GCP from 24 h
to 48 h (Supplementary data S10, S11).
Merging microarray data sets of Imatinib and TRIKI
treatments of adult schistosomes provided first evidence
for a TGFb-pathway contribution
Since the couples used for these analyses were separated before
freezing, we checked whether pairing had an influence on the
transcription of the GCP gene, which was hypothesized before to
be a target of a TGFb-pathway but also a male factor contributing
to pairing-dependent female maturation [72,82,83]. A qRT-PCR
analysis using actin as reference gene showed that the status of
pairing had no significant influence on the GCP transcript level,
since there was no significant difference in transcript levels
comparing males with and without pairing experience or males
separated from their female partners (Supplementary data S12).
This finding is also supported by results of a recent study
comparing the transcriptomes of pairing-experienced males versus
naı¨ve males using microarrays, SuperSAGE and also qRT-PCR,
in which no evidence for an influence of pairing on GCP
expression was found [84]. Thus the decrease of the GCP
transcript level following Imatinib treatment represented an
inhibitor-specific effect.
Figure 3. GVBD assays confirming SmAbl2 inhibition by
Imatinib. Results of the GVBD assays performed in Xenopus oocytes
to analyze schistosome-kinase activities under inhibitor influence.
Herbimycin A completely inhibited SmTK3 TK enzymatic activity (circles,
black) even at 0.01 mM, whereas 10 mM was needed to stop inhibit
SmTK6 (squares, grey)-induced GVBD [38]. At this concentration the
GVDB-inducing TK activities of SmAbl1 (rhombus, grey) and SmAbl2
(triangle, black) were reduced by only 40% or 10%, respectively.
Imatinib completely inhibited GVBD induced by the TK activities of
SmAbl1 (at 1 mM) or SmAbl2 (at 0.1 mM), whereas SmTK6-induced GVBD
was stopped at 100 mM, a concentration that reduced SmTK3 TK-
induced GVBD by only 10% [38].
doi:10.1371/journal.pntd.0002923.g003
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Recent years have provided compelling evidence for a
prominent role of TGFb signalling in schistosome biology
[27,47,84,85,86]. Results of a previous study suggested GCP to
be part of TGFb signalling pathways [82]. Furthermore, the effect
of a specific TbRI kinase-inhibitor (TRIKI) was investigated in
schistosomes. In vitro-culture experiments with couples provided
first evidence for a role of the TGFb pathway during the
regulation of mitotic activity and egg production [26]. Subse-
quently, it was shown by microarray analysis using the same
technical platform that genes contributing to these processes, such
as egg shell-forming genes, were slightly up-regulated upon TRIKI
treatment [47]. Analysing the microarray data following Imatinib
treatment in the present study we observed that a number of
specific genes were differentially regulated that had shown up in
the previous analysis as well. Since there is evidence from the
literature that Abl-kinases can be part of TGFb signalling
pathways [87,88] we investigated whether this may apply for
schistosomes as well and compared both data sets in a merging
Figure 4. qRT-PCR experiments verifying the down-regulation of genes following Imatinib treatment. Comparative qRT-PCR analyses of
genes identified by microarray analyses to be down-regulated in schistosome couples 48 h following Imatinib (50 mM) treatment. The selected genes
encode the gynecophoral canal protein GCP (Smp_212710; [72,82,83]), the metabotropic glutamate receptor (met. glut. receptor; Smp_128940; [70]),
hemoglobinase (Smp_075800), the venom allergen-like protein VAL7 (Smp_070240), cathepsin S (Smp_139240), and cathepsin B (Smp_085180; [67]).
Log2ratios (treated/control) are given for all biological replicates comparing the results of three independent biological replicates using qRT-PCR
(dark gray-shaded columns; numbered 1–3) with the results of three independent microarray analyses (light grey-shaded and white columns;
numbered 4–6).
doi:10.1371/journal.pntd.0002923.g004
Figure 5. qRT-PCR experiments verifying the up-regulation of genes following Imatinib treatment. Comparative qRT-PCR analyses of
genes identified by microarray analyses to be up-regulated in schistosome couples 48 h following Imatinib (50 mM) treatment. The selected genes
encode a predicted egg-shell precursor protein (Smp-000430; [47]), a ribosomal protein S6 kinase (rib. protein S6 kinase; Smp_017900), paramyosin
(Smp_129550; [73]), HSP70 (Smp_106930; [77,78]), fs800-like (Smp_000270; [79]), titin (Smp_105020), p14 (Smp_131110; [80]), and the tyrosinase 1
(SmTYR1; Smp_050270; [81]). Log2ratios (treated/control) are given for all biological replicates comparing the results of three independent biological
replicates using qRT-PCR (dark gray-shaded columns; numbered 1–3) with the results of three independent microarray analyses (light grey-shaded
and white columns; numbered 4–6).
doi:10.1371/journal.pntd.0002923.g005
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analysis. To this end the Imatinib data set of this study and the
TRIKI data set of the previous microarray study [47] were
compared using a significance q-value of #0.05 to identify a
comprehensive set of differentially transcribed genes found in
common in the two conditions. This approach identified 6754
differentially transcribed protein-coding genes in total, of which
1800 were common in both data sets. The merging analyses finally
indicated that out of 2339 genes found in this study to be down-
regulated upon Imatinib treatment, 900 matched those differen-
tially (up- and down-) regulated upon TRIKI treatment. Out of
these 480 were up-regulated and 420 down-regulated by TRIKI.
Furthermore, out of 2616 genes found in this study to be up-
regulated upon Imatinib treatment, 900 corresponded to those
differentially regulated by TRIKI. Out of these 822 were up-
regulated and 78 down-regulated by TRIKI. By definition, no
gene was found within the intersection of Imatinib up- and down-
regulated genes (Figure 6; Supplementary data S13, S14).
Discussion
Based on our previous results on the physiology and morphol-
ogy of adult schistosomes treated by Imatinib [38], our present
study aimed at identifying transcriptional processes influenced by
this inhibitor. To confirm that Imatinib targets not only the Abl
kinase SmAbl1 as shown by biochemical analyses before [39], we
investigated its inhibitor effect on SmAbl2. SmAbl1 and SmAbl2
are the only true Abl-kinases present within the genome of S.
mansoni [50] in contrast to SmTK6 which represents a Src/Abl
hybrid kinase being less susceptible to Imatinib [39; this study]. By
competitive GVBD assays in Xenopus oocytes expressing these
kinases we determined specific effects of Imatinib on both Abl1
and Abl2 kinases. Although their susceptibilities differed by a
factor of 10, the results obtained in this and the previous study [39]
clearly confirmed their target roles, but also that Src-like and true
Src kinases such as SmTK3 are not affected at the Abl-effective
concentrations of Imatinib, which reduced the probability of off-
target effects. These experimental data were well supported by the
modeling and docking data generated confirming that Imatinib is
able to bind to both schistosome Abl kinases.
With regard to results of the in vitro study showing increasing
physiological and morphological effects between 24 h and 48 h
treatment using 50 mM Imatinib [38], we performed transcrip-
tional profiling for these time-points to get a broader view of
molecular processes potentially affected by Imatinib. Microarray
and subsequent bioinformatics analyses revealed a broad spectrum
of genes being differentially regulated following inhibitor treat-
ment. The transcription of genes involved in male-female
interaction, gut physiology, muscle activities, and egg production
were among those highlighted by the analyses. For qRT-PCR
verification a number of genes were selected with regard to GO
and IPA results but also to the phenotypes obtained in the
preceding in vitro study, which comprised reduced pairing stability
(i), reduced sizes of the gonads of both genders combined with
disturbed spermatocyte/oocyte differentiation (ii), a degradation of
the gastrodermis (iii), and tremor-like movements pointing to
altered locomotion activity (iv) [38]. In each case qRT-PCR and
microarray results correspondingly showed sustained transcrip-
tional changes and reduced transcript levels in each case for (i)
GCP, a fascicle I-like cell adhesion molecule hypothesized to be
involved in male-female interaction [72,83], (ii) VAL-7, a member
of the sperm-coating protein SCP/TAPS superfamily [89,90] that
was found in S. mansoni to be expressed in the esophageal gland in
larvae, and adult males and females [91], (iii) a hemoglobinase and
the cathepsins B and S, of which hemoglobinase and cathepsin B
were already shown to be active in the gut [67,92–94], (iv) as well
as a metabotropic glutamate receptor. Interestingly, previous
studies indicated that Abl kinases regulated lysosome functions,
especially autophagy by organizing the localization and activity of
lysosomes, glycosidases and cathepsins, suggesting that Abl is
involved in processes regulating digestion and removal of self- and
foreign material [95,96]. Metabotropic glutamate receptors have
been discussed in the context of seizure-like behavior, defined as
paroxysms resulting in disruption of normal locomotor-system
activity in planaria [97]. Whether this tremor-like phenotype in
schistosomes (iv) is also accompanied by higher transcript levels
detected for the muscle protein genes paramyosin and titin, of
which the latter determines muscle elasticity, stability, and
contraction velocity [98], remains unclear at this stage. In
contrast, the up-regulation of the stress protein gene HSP70
following inhibitor treatment meets the expectations as well as
higher transcript levels of the ribosomal S6 kinase, a signaling
molecule involved in cell growth, proliferation, but also survival
[99]. Thus the differential regulation of these genes corresponded
well to the phenotypes observed in vitro. Furthermore, a
comparison of both time-points used for the analysis (24 h/48 h)
showed strong and sustained transcriptional changes by micro-
arrays but also on the basis of qRT-PCRs of selected candidate
genes, which indicated an enduring influence of the Abl kinase
pathway on these genes.
Compared to transcriptome studies in S. mansoni or S. japonicum
after exposure to PZQ in vitro [100,101] or in vivo [102], a number
of differences can be noted that indicate dissimilar processes
affected by this established drug and Imatinib. Using a recent in
vivo model of S. japonicum PZQ led to an up-regulation among
others of genes associated with muscle function, lipid and ion
regulation, and drug resistance in treated males [102]. In females,
fewer genes seemed to be affected (up-regulated), examples are
involved in pathogen defense, general detoxification, drug
resistance and calcium regulation [102]. Similar findings were
Figure 6. Venn diagram of genes down- or up-regulated
following Imatinib or TRIKI treatment. Merging analyses repre-
sented by a Venn diagram of the intersections of significant
differentially transcribed down- or up-regulated genes following
Imatinib treatment with those differentially (up- and down-) regulated
upon TRIKI treatment [47]. The direction of regulation following
Imatinib treatment (down/up) is shown within the header. Given
numbers correlate with the numbers of significant differentially
transcribed genes for these data sets (see text). The overlapping
regions of the circles contain the corresponding differentially tran-
scribed genes in these data sets.
doi:10.1371/journal.pntd.0002923.g006
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made in in vitro studies with adult S. mansoni showing that genes
encoding multiple drug transporter as well as calcium regulation,
stress and apoptosis-related proteins were up-regulated [101]. In
contrast to these findings we observed a down-regulation of genes
coding for lipoproteins, motor and/or muscle proteins, drug efflux
proteins, calmodulin and other calcium binding proteins in S.
mansoni couples following Imatinib treatment. With respect to
apoptosis-related genes the picture is puzzling since there much
variation within all PZQ and Imatinib data sets and little
correspondence among these different data. This justifies no
precise conclusion on the participation of defined apoptosis-related
signaling processes in the primary effects on schistosomes caused
by these drugs.
Surprisingly, we also identified genes to be up-regulated that
contribute to egg formation such as p14, fs800-like, a predicted
egg-shell precursor protein gene, and tyrosinase 1, a gene involved
in final egg-shell synthesis [79,81]. This was unexpected since we
observed reduced egg production in Imatinib-treated schistosome
couples. However, egg production is a complex process and may
be influenced by further genes of which some, yet unknown to be
important for this process, may be down-regulated by Imatinib,
while the known egg-formation genes might be up-regulated to
compensate for the overall reduced egg output in Imatinib-treated
schistosomes.
Conspicuously, the higher transcript levels of these egg
formation-related genes resembled the results obtained in a
recent microarray study where the effect of TRIKI, a TGFbRI-
kinase inhibitor, was investigated on transcriptional profiles in
adult schistosome couples in vitro. TRIKI led to an increase of
transcript levels of the same egg formation-related genes in paired
females in contrast to Herb A, a Src kinase inhibitor, which
reduced the transcript levels of these genes. From this it was
concluded that a TGFb and a Src kinase pathway cooperatively
control egg formation processes in a balanced manner in
schistosomes assigning repressing (TGFb/TGFbRI-pathway)
and inducing (Src-pathway) tasks [47]. This and the finding of
GCP and egg formation-associated genes as common target
molecules of TGFb [82] as well as SmAbl1/2-influenced
molecular processes [this study], prompted us to evaluate the
TRIKI-related against the Imatinib-related microarray data sets.
Comparing the total amounts of differentially transcribed genes
about 27% (1800 out of 6754) were present in both data sets, of
which about 50% (900 or 900 out of 1800) were differentially
regulated and about 70% (420 and 822 out of 1800) in the same
direction. Thus many genes significantly differentially transcribed
upon TRIKI- and Imatinib treatment overlapped. This clearly
indicates a potential association of TGFbRI-mediated and Abl
kinase-containing pathways in schistosomes. Beyond the fact that
egg formation-associated genes such as fs800-like, p14, egg shell
precursor, and tyrosinase 1 [47; this study] as well as GCP
became noticeable as common targets, SmAbl1/2 transcripts and
TGFbRI-transcripts were found in the same tissues by in situ
hybridization, mainly in the gonads [38,103]. In conclusion, it
appears very likely that the schistosome Abl kinase(s) are among
other possibilities members of signalling pathways induced by
TGFb. Such a molecular connection has been shown before,
demonstrating c-Abl as a Smad-independent component of
TGFb signaling pathways and mediator of TGFb-driven
proliferation in human fibroblasts [87,104,105].
Our previous in vitro studies exhibited strong effects of Imatinib
on schistosome morphology, physiology and survival in vitro
suggesting that this compound may be one of the candidates for
the design of alternative strategies to fight schistosomiasis
[38,42,43]. This was confirmed by an independent approach
recently, which reproduced similar phenotypes in vitro, although a
first in vivo experiment failed [106]. Nonetheless, the data obtained
in this study support the conclusion that Imatinib exerts broad
negative effects on worm physiology substantiating the hypothe-
sized role of PKs as potential targets [25,28,36,42,43]. In this
respect it was encouraging to note that according to our
microarray analysis also multidrug resistance (MDR) genes
(Smp_089200, Smp_151290) were among the significantly
down-regulated genes following Imatinib treatment. Thus they
may represent additional targets of Abl-kinase-containing path-
ways. Future studies could also aim at analyzing the molecular
networks controlling the expression of such MDR genes and their
substrate specificities in more detail. Depending on the substrates
transported by these MDRs, and with respect to treatment strategy
and efficacy, the suppression of MDR genes as an additional
consequence of inhibitor application would represent a potential
side effect that is most welcome.
Supporting Information
Data S1 List of primers used for qRT-PCRs. Smp numbers of
the target genes, primer sequences (f = forward, r = reverse), and
annealing temperatures (Tm) used are given.
(DOCX)
Data S2 Hierarchical clustering of differentially transcribed
genes (q = 0.1%) following Imatinib treatment. Summarized are
three biological replicates for each time point analysed (24 h, 1–3;
48 h, 1–3). Genes with repressed transcription (down-regulated)
are colored in green, and genes with enhanced transcription (up-
regulated) in red.
(TIF)
Data S3 List of all significantly differentially transcribed genes
following Imatinib treatments (24 h and 48 h; q = 0.1%) according
to the one-class analysis. This list is subdivided in up- and down-
regulated genes.
(XLSX)
Data S4 List of selected genes up-regulated after Imatinib
treatment (q = 0.1%). Besides the Gene ID number, relative
transcript ratios are given for both time-points (24 h and 48 h) as
well as annotations and functional categories.
(DOCX)
Data S5 List of selected genes down-regulated after Imatinib
treatment (q = 0.1%). Besides the Gene ID number, relative
transcript ratios are given for both time-points (24 h and 48 h) as
well as annotations and functional categories.
(DOCX)
Data S6 Gene Ontology (GO) categories are listed enriched with
significantly differentially transcribed genes (BH adjusted p-value
#0.05; threshold = 0.1) up-regulated following Imatinib treat-
ment.
(XLSX)
Data S7 Gene Ontology (GO) categories are listed enriched with
significantly differentially transcribed genes (BH adjusted p-value
#0.05; threshold = 0.1) down-regulated following Imatinib
treatment.
(XLSX)
Data S8 Summary of the IPA analysis [57] containing lists of
networks, biological functions, canonical pathways, and the top
molecules being down- and up-regulated based on the relative fold
changes of expression.
(XLSX)
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Data S9 Summary of the qRT-PCR and microarray analyses
which show the sustained effect of Imatinib treatment (24 h or
48 h) on the transcript level of the ribosomal S6-kinase gene.
Log2ratios (treated/control) are comparing the results of three
independent biological replicates using qRT-PCR (24 h and 48 h,
columns 1–3, light gray) with the results of three independent
microarray analyses (24 h and 48 h, columns 4–6, dark gray).
(TIF)
Data S10 Summary of the qRT-PCR and microarray analyses
which show the sustained effect of Imatinib treatment (24 h or
48 h) on the transcript level of the hemoglobinase gene. Log2ratios
(treated/control) are given comparing the results of three
independent biological replicates using qRT-PCR (24 h and
48 h, columns 1–3, light gray) with the results of three
independent microarray analyses (24 h and 48 h, columns 4–6,
dark gray).
(TIF)
Data S11 Summary of the qRT-PCR and microarray analyses
which show the sustained effect of Imatinib treatment (24 h or
48 h) on the transcript level of the GCP gene. Log2ratios (treated/
control) are given comparing the results of three independent
biological replicates using qRT-PCR (24 h and 48 h, columns 1–
3, light gray) with the results of three independent microarray
analyses (24 h and 48 h, columns 4–6, dark gray).
(TIF)
Data S12 Result of the transcript level of GCP determined by
qRT-PCR with RNA from males cultured in vitro, which either
have never been paired with a female (1), or were separated from a
female for five days (2), or were kept in culture paired with females
(3) before they were separated to perform the analysis (n = 3). Actin
transcript levels were determined as reference in each case.
(TIF)
Data S13 List of genes identified in the merging analysis to be
down-regulated after Imatinib treatment and differentially regu-
lated (up or down) following TRIKI treatment. Besides the Gene
ID number, relative transcript ratios are given for both time-points
(24 h and 48 h) as well as annotations and functional categories.
(XLSX)
Data S14 List of genes identified in the merging analysis to be
up-regulated after Imatinib treatment and differentially regulated
(up or down) following TRIKI treatment. Besides the Gene ID
number, relative transcript ratios are given for both time-points
(24 h and 48 h) as well as annotations and functional categories.
(XLSX)
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